Intravenous (IV) reslizumab efficacy does not differ by blood eosinophil lowering to levels above or below 50 cells/µL

Y. Adir (Haifa, Israel), M. Castro (St Louis, United States of America), P. Chanez (Marseille, France), M. Mcdonald (Malvern, United States of America), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America)

Source: International Congress 2018 – New developments in the treatment of asthma
Session: New developments in the treatment of asthma
Session type: Thematic Poster
Number: 1031
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Adir (Haifa, Israel), M. Castro (St Louis, United States of America), P. Chanez (Marseille, France), M. Mcdonald (Malvern, United States of America), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America). Intravenous (IV) reslizumab efficacy does not differ by blood eosinophil lowering to levels above or below 50 cells/µL. 1031

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: